Amgen

Open: 276.85 Close: 277.93 Change: 1.08

Our AI found unexpected things about Amgen.

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, share, company, report, present, earnings, beat, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen reported fourth-quarter 2023 adjusted earnings of $4.71 per share, beating the Zacks Consensus Estimate of $ 4.66 per share. General Dynamics today declared a regular quarterly dividend of $1.42 per share on the companys common stock.

Today's News

Amgen reported fourth-quarter 2023 adjusted earnings of $4.71 per share, beating the Zacks Consensus Estimate of $ 4.66. Amgen closed the acquisition of Horizon Therapeutics for $27.8 billion on Oct 6, 2023. Amgen has created a robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illnesses. Amgen is committed to the highest standards of drug quality and patient safety. The Senior Manager will shape the strategic engagement priorities for Amgen in British Columbia and Alberta to drive policy and market access initiatives aligned to business. Amgen (AMGN) reported earnings of $4.71 per share, beating the Zacks Consensus Estimate of $ 4.66 per share. Amgen is a pioneer in the science of using living cells to make biologic medicines. Amgen to present at the 44th Annual TD Cowen Health Care Conference at 9:10 a.m. General Dynamics today declared a regular quarterly dividend of $1.42 per share on the companys common stock. Amgen presents new research on otezla® (apremilast) at aad 2024. Amgen is one of the leading independent biotechnology companies around the world. Amgen Quality Assurance Specialist - PQA in Holly Springs, North Carolina. Be part of Amgens newest and most advanced drug substance manufacturing plant. Quality Assurance Specialist - PQA job with Amgen - North Carolina Start date Mar 8, 2024. Amgen FleX batch facility will combine the latest in disposable technologies with traditional stainless steel equipment. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions. Amgen presents new research on otezla® (apremilast) at aad 2024. Senator Tommy Tuberville reported the sale of $15,001 - $50,000 of Amgen Inc. Amgen. Kyowa Kirin and Amgen entered into an agreement to jointly develop and commercialize rocatinlimab. If approved, the companies will co-promote the asset in the United States. Amgen is one of the 30 companies that comprise the Dow Jones. Amgen (AMGN) declares $2.25 per share dividend for Q2 2024, payable on June 7, 2024, to stockholders of record as of May 17, 2024. Amgen launches Amgen Perspectives in Obesity website. The Amgen team filed a patent (US2017027537070A1) titled Methods for Treating or Ameliorating Metabolic Disorders Using a GIPR Binding Protein in Combination with a GLP-1 Agonist The patent describes a method of nucleic acid immunization used by the Amgen.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, share, company, report, present, earnings, beat, and the most common words in the summary are: amgen, stock, market, overview, data, science, clinical, . One of the sentences in the summary was: General Dynamics today declared a regular quarterly dividend of $1.42 per share on the companys common stock.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #market #overview #data #science #clinical.